The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
The Cambridge, Massachusetts-based biotech's personalized cancer vaccine mRNA-4157, developed with Merck (MRK), is currently in late-stage development targeting patients with skin cancer melanoma.
Some of the key cancer vaccines in the pipeline include IO102-IO103, mRNA-4157 (V940) + KEYTRUDA, CAN-2409, Nelipepimut-S + Cemiplimab, PDS0101 + Pembrolizumab, PDC*lung01, LB-LR1109, RUTI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback